Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Bain Capital Life Sciences
AddedFeb 13, 2024
UpdatedJun 28, 2026
Bain Capital Life Sciences

Bain Capital Life Sciences

Operating

Bain Capital Life Sciences Fund LP: Boston-based buyout specialist in life sciences.

Location
Boston, MA, US
Founded
2016
Firm
Compare
Portfolio
Employees
Website

Investments

Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Post Ipo Equity$45MDecember 2023
Aiolos Bio
Aiolos Bio
Acquired

Total Raised

$245M

Rounds

1

Series A$245MOctober 2023
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Private Equity$210MSeptember 2023
Late Stage Private$125MSeptember 2022
Abcuro
Abcuro

Total Raised

$214.8M

Rounds

5

Series B$155MAugust 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Kyverna Therapeutics
Kyverna Therapeutics

Total Raised

$170M

Rounds

3

Series B$60MAugust 2023
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals

Total Raised

$150.1M

Rounds

2

Series B$150MJune 2023
Heartflow
Heartflow

Total Raised

$792.7M

Rounds

11

Series F$215MApril 2023
Jnana Therapeutics
Jnana Therapeutics

Total Raised

$207M

Rounds

3

Series C$107MNovember 2022
Emalex Biosciences
Emalex Biosciences

Total Raised

$300M

Rounds

3

Series D$250MNovember 2022
Solid Biosciences
Solid Biosciences
Public

Total Raised

$441.3M

Rounds

8

Post Ipo Equity$75MSeptember 2022
Rivus Pharmaceuticals
Rivus Pharmaceuticals

Total Raised

$167M

Rounds

2

Series B$132MSeptember 2022
Areteia Therapeutics
Areteia Therapeutics

Total Raised

$350M

Rounds

1

Series A$350MJuly 2022
X4 Pharmaceuticals
X4 Pharmaceuticals
Public

Total Raised

$542.9M

Rounds

14

Post Ipo Equity$55MJune 2022
Post Ipo Equity$55MMarch 2021
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Cardurion Pharmaceuticals
Cardurion Pharmaceuticals

Total Raised

$343.1M

Rounds

5

Series B$300MOctober 2021
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals
Public

Total Raised

$448.5M

Rounds

9

Series C$135MJuly 2021
Imperative Care
Imperative Care

Total Raised

$409M

Rounds

5

Series D$260MJuly 2021
Interius BioTherapeutics
Interius BioTherapeutics

Total Raised

$103M

Rounds

3

Series A$76MMay 2021
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals
Public

Total Raised

$796M

Rounds

15

Post Ipo Equity$75MApril 2021